All In MedTech

FDA Clearance Tracker · P990026

GLUCOWATCH AUTOMATIC GLUCOSE BIOGRAPHER

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Mar 22, 2001 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Mar 22, 2001

Approval withdrawn

Time to decision

660 days

Received Jun 1, 1999. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P990026
Device name
GLUCOWATCH AUTOMATIC GLUCOSE BIOGRAPHER
Applicant
Animas Corp.
Applicant location
West Chester, PA
Received
Jun 1, 1999
Decided
Mar 22, 2001
Decision
Approval withdrawn
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
21 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NCT

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE GLUCOWATCH(R) AUTOMATIC GLUCOSE BIOGRAPHER. THE DEVICE IS INDICATED FOR: THE GLUCOWATCH(R) AUTOMATIC GLUCOSE BIOGRAPHER IS A GLUCOSE MONITORING DEVICE INDICATED FOR DETECTING TRENDS AND TRACKING PATTERNS IN GLUCOSE LEVELS IN ADULTS (AGE 18 AND OLDER) WITH DIABETES. THE DEVICE IS INTENDED FOR USE BY PATIENTS AT HOME AND IN HEALTH CARE FACILITIES. THE GLUCOWATCH BIOGRAPHER IS INDICATED FOR USE AS AN ADJUNCTIVE DEVICE TO SUPPLEMENT, NOT REPLACE, INFORMATION OBTAINED FROM STANDARD HOME GLUCOSE MONITORING DEVICES. THE BIOGRAPHER IS INDICATED FOR USE IN THE DETECTION AND ASSESSMENT OF EPISODES OF HYPERGLYCEMIA AND HYPOGLYCEMIA, FACILITATING BOTH ACUTE AND LONG-TERM THERAPY ADJUSTMENTS, WHICH MAY MINIMIZE THESE EXCURSIONS. INTERPRETATION OF BIOGRAPHER RESULTS WHOULD BE BASED ON THE TRENDS AND PATTERNS SEEN WITH SEVERAL SEQUENTIAL READINGS OVER TIME.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code NCT (INSTRUMENT, GLUCOSE, NONINVASIVE TECHNOLOGY).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Animas Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.